fda warning letters compounded semaglutide tirzepatide september 2025 GLP-1 Compounding: When Innovation May Mean Liability FDA Warns 30 Telehealth Companies

The body is adapting to a new metabolic signal, caloric intake is beginning to fall without conscious restriction, and the hormone signaling that governs fat storage and release is starting to recalibrate

@niamhshackleton

If you are managing multiple side effects simultaneously, the ability to ask questions of people who have been through the same process is genuinely valuable

The prevention and treatment of obesity

The result is a brain bathed in inflammatory mediators that amplify cravings, impair impulse control, and degrade the prefrontal cortexs ability to override compulsive urges

Tirzepatide is the right choice when the research question involves GIPR biology, GIP-GLP-1 synergy, or the pharmacology of dual-agonist engineering itself